Grifols Paid Family-Linked Firm More for Plasma

Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case.

Grifols paid Scranton Enterprises BV — one of its main shareholders — between 2% and 39% more annually for plasma than it paid other suppliers over five years, according to a document from the securities regulator filed with a Spanish court. Grifols also agreed to pay a fixed 16.5% mark up on costs to Scranton, according to the documents, which were seen by Bloomberg.